236 
Market Cap
Stock Chart
Phosphagenics - 30 Day Poll
Recent BLOGS About Phosphagenics Add New
Latest Company News
|
Phosphagenics lands retail deal with David Jones
Australian Life Scientist - May 10, 2012 Retail chain David Jones has agreed to stock the Elixia range of skincare products from Melbourne-based Phosphagenics (ASX:POH). Phosphagenics (ASX:POH) has signed on David Jones as its newest retail partner for its Elixia range of skincare products.
|
|
Phosphagenics Limited Signs License Agreement With Intas Pharmaceuticals Ltd
Reuters Key Development - Apr 3, 2012 |
|
Phosphagenics Limited Signs Agreement With Korean Drug Co Ltd
Reuters Key Development - Mar 14, 2012 |
Website
Videos related to Phosphagenics
Company Profile
Financials:
At the end of June 2011 cash reserves were $6.3 million.
Phosphagenics raised $24.1 million via a $17.1 million placement to institutions and sophisticated investors and a $7 million placement to a Singapore-based investor in October 2011.
Business model:
The company does "Production, sale and licensing of products for the nutraceutical and pharmaceutical industries." It is not a developing any block buster drug that cures diseases. Instead it develops and owns technologies for drug delivery that are Transdermal, Dermal and Oral (Phospha E, TPM).
It has 2 products in Phase II, several more in Phase I and more in Preclinical. It had sign agreements with local biotechs such as CSL and Metabolics. In Nov 2009, it announced the launch of an anti-aging product by its US partner which uses POH's TPM delivering technology.
POH has demonstrated penetration into the US market. It has deals with at least one major US company, and an office in the US. However, there seems to be no other foreign market associations than the US.
Possible coming events:
The Company is collaborating with 3M to optimise the patch and expects to begin Phase 2 clinical trials for its enhanced oxycodone patch later in 2011.